Tru Niagen® Protocol

Age-Associated Oxidative Stress

Upload protocol

Tru Niagen® Pro 300

300 mg, once or twice per day, for a minimum 21 days (1)(2)(3)

Tru Niagen® Pro 500

500 mg, once or twice per day, for a minimum 21 days (1)(2)(3)

  • In a double-blind, crossover trial, a single 500 mg dose of nicotinamide riboside reduced oxidative stress markers while increasing NADPH and improved exercise performance in older men. (4)
  • Nicotinamide riboside reduced neurodegeneration in preclinical models of Parkinson’s disease through its ability to restore the health of the mitochondria, the site of reactive oxygen species (ROS) overproduction. (6)
  • A review indicated that nicotinamide riboside could exert beneficial effects in amyotrophic lateral sclerosis (ALS) and Parkinson’s Disease in part through its ability to suppress mitochondrial production of ROS as well as preventing axonal degeneration that occurs due to NAD+ depletion in neurons. (7)
  • Therapies that maintain intracellular NAD(+) pools during conditions of oxidative stress may help block age-dependent cellular damage. (8)
  • Nicotinamide riboside increased levels of NAD+ by 100% and was found to be beneficial in healthy, human volunteers. (9)
  • In a mouse model of diet-induced obesity, oral supplementation with nicotinamide riboside improved oxidative metabolism and increased NAD+ in brown adipose tissue, skeletal muscle, and the liver resulting in enhanced oxidative metabolism and mitochondrial function. (10)

Disclaimer

The Fullscript Integrative Medical Advisory team has developed or collected these protocols from practitioners and supplier partners to help health care practitioners make decisions when building treatment plans. By adding this protocol to your Fullscript template library, you understand and accept that the recommendations in the protocol are for initial guidance and may not be appropriate for every patient.

Upload protocol

References

  1. https://pubmed.ncbi.nlm.nih.gov/31278280/
  2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702140/
  3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876407/
  4. https://link.springer.com/article/10.1007/s
  5. https://www.sciencedirect.com/science/article/pii/S2211124718307423
  6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016185/
  7. https://pubmed.ncbi.nlm.nih.gov/18522897/
  8. https://pubmed.ncbi.nlm.nih.gov/29211728/
  9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3616313/

Fullscript content philosophy

At Fullscript, we are committed to curating accurate, and reliable educational content for practitioners and patients alike. Our educational offerings cover a broad range of topics related to integrative medicine, such as supplement ingredients, diet, lifestyle, and health conditions.

Medically reviewed by expert practitioners and our internal Integrative Medical Advisory team, all Fullscript content adheres to the following guidelines:

  1. In order to provide unbiased and transparent education, information is based on a research review and obtained from trustworthy sources, such as peer-reviewed articles and government websites. All medical statements are linked to the original reference and all sources of information are disclosed within the article.
  2. Information about supplements is always based on ingredients. No specific products are mentioned or promoted within educational content.
  3. A strict policy against plagiarism is maintained; all our content is unique, curated by our team of writers and editors at Fullscript. Attribution to individual writers and editors is clearly stated in each article.
  4. Resources for patients are intended to be educational and do not replace the relationship between health practitioners and patients. In all content, we clearly recommend that readers refer back to their healthcare practitioners for all health-related questions.
  5. All content is updated on a regular basis to account for new research and industry trends, and the last update date is listed at the top of every article.
  6. Potential conflicts of interest are clearly disclosed.